# One Health Group reports strong increases in revenue, profitability and cash

- Link: https://www.directorstalkinterviews.com/one-health-group-reports-strong-increases-in-revenue-profitability-and-cash/4121181646
- Published: 2024-12-20T07:50:30+00:00
- Author: Amilia Stone

**One Health** **Group plc** (AQSE: OHGR), a provider of NHS-funded medical procedures,
has announced its unaudited interim results for the six months ended 30 September
2024.

**Financial Highlights**

The Group performed well in the first half with strong increases in revenue, profitability
and cash, ahead of previous management expectations, representing significant increases
on H1 24. The interim dividend has been increased by 2% to 2.07p per share. Highlights
below reflect first time reporting under IFRS and consolidation of the Employee 
Benefit Trust (“EBT”).

| **Financial Summary** | **H1 25** | **H1 24 (Restated\*)** | **% change** | 
| Turnover | £13.30 m | £10.94 m | +22% | 
| Underlying EBITDA* | £0.960 m | £0.687 m | + 40 % | 
| Underlying EPS* | 7.46 pence | 4.28 pence | + 74% | 
| Cash balance | £4.89 m | £3.64 m | + 34 % | 
| Interim dividend | 2.07 pence | 2.03 pence | + 2 % |

*Restated under IFRS with consolidation of EBT and a legacy property valuation adjustment.

**Declaration of Interim Dividend**

[One Health Group plc](https://www.directorstalkinterviews.com/company/one-health-group-plc/ohgr.l)
is pleased to announce that the Board of Directors has declared an interim dividend
at the rate of 2.07 pence per share, in line with the Board’s stated dividend policy,
to be paid on 24 January 2025 to shareholders on the register as at close of business
on 3 January 2025.  The ex-dividend date will be 2 January 2025.

**Operational Highlights**

·    Received 7,857 new patient referrals (H1 24: 6,091) an increase of 29% and 
a new record

·    Delivered 19,674 consultations (H1 24: 15,239) an increase of 29%

·    Surgical procedures carried out on 3,427 NHS patients through 9 independent
hospitals (H1 24: 2,997) a 14% increase

·    Onboarded 7 new clinicians to the business to support growth

·    Outreach clinics expanded to 37 (H1 24: 33) a 12% increase

·    NHS Tariff price uplift following junior doctors’ settlement to benefit H2 
revenue and margin

·    Government change has had a positive effect including active promotion of ‘
Patient Choice’ and an increased use of independent sector support cited as one 
of the key actions to reduce NHS waiting lists

·    Established 5-year contracts with our largest NHS commissioners, moving away
from the historic annual renewal process

·    Adoption of International Financial Reporting Standards (IFRS) in advance of
a potential move to AIM in the second half of the year (Note 2.4)

**Post-period updates**

·      Additional surgical capacity being established with two new independent hospitals
in new geographical areas

·      Full planning on the planned new build surgical hub being submitted in H2
which is expected to deliver significant additional operating capacity in 2026 and
has the potential to significantly increase the profitability of the Group

·      Further surgical hubs are being actively pursued to increase the Group’s 
surgical capacity to help to satisfy the demand from the NHS

·      Continued review of the Group’s IT systems and control environment ahead 
of a potential AIM Listing in 2025 (Note 11)

·      NHS outsourced activity is historically weighted towards the second half 
of the year as commissioners look to spend budget allocations before year end

·      Demand continuing from NHS Trust Waiting List transfers representing 8% of
H1 25 revenue, with an uplift expected in H2

**IFRS Conversion**

Previously, the Group had reported its results under United Kingdom Generally Accepted
Accounting Principles (UK GAAP). In consideration of a potential move to AIM, the
interim results for the six months ended 30 September 2024 (and comparatives for
H1 2023), are presented under IFRS. The key presentational changes and accounting
policy adjustments that arise from the first-time adoption of IFRS by the Group 
are set out in note 2 of this announcement.

On adoption of IFRS, the EBT, which owns a significant portion of the Group’s ordinary
share capital and which was established for the benefit of the employees of the 
Group and is considered to be controlled by the Group, has been consolidated into
the Group results for the first time.

The Group has therefore recognised a prior year restatement to consolidate the EBT,
which has reduced the previously reported profits of the Group, removed a receivable
balance previously recognised by the Group, and introduced a new component of equity,
termed as an own shares reserve.

**Review of the period**

Operationally, 2024 has seen a further increase in the national NHS waiting list
and industrial action causing disruption to NHS patients care caused by cancelations.
As a result, demand for support from One Heath and other independent sector providers
increased during the first half of the year. During the same period, we saw continued
demand for waiting list transfers and direct referrals from NHS Trusts. The Group
has onboarded seven new clinicians to the Group into new geographical areas and 
continues to expand surgical capacity in existing areas, meaning One Health is well
placed to support the NHS in the second half of the year, traditionally our busiest
period. The Group continues to work closely with more NHS trusts to support the 
reduction of waiting lists for elective care.

From a financial perspective One Health has performed very well in the first half
of the year. As reported in the trading update on 28 October 2024, financial performance
was ahead of previous management expectations and as we enter our busiest period
of the year.

Cash at the end of September 2023 of £4.9m supporting ongoing investment in growth
and our progressive dividend policy. The Board is therefore declaring an increased
interim dividend of 2.07p per Ordinary Share (H1 22/23: 2.03p per share) to be paid
on 24 January 2025 to shareholders on the register as at close of business on 3 
January 2025

> **Adam Binns, Chief Executive Officer, said:**
> _“One Health has performed strongly in the first six months of the financial year,
> significantly ahead of last year with turnover up 22% to £13.3m, underlying EBITDA
> up 40% to nearly £1m and new patient referrals up 29% at 7,857._
> _“These referrals include a continuation of NHS patients transferring to One Health
> from local Trusts to help them reduce their internal waiting lists. The Trust 
> transfer activity is in addition to patients received through the traditional 
> route by choosing to be referred to One Health through ‘Patient Choice’ after 
> visiting their GP._
> _“We are very pleased with performance in the first half of the year and expect
> to achieve our year end forecasts.”_

**Outlook**

Since the period end, record high levels of NHS patient referrals to One Health 
have continued. In addition, and as anticipated, several NHS Trusts have also approached
One Health to establish additional capacity available over the second half of H2
25 and H1 2026 to support their demanding internal year-end waiting list targets.
We have also benefitted directly from the settlement of the junior doctors’ industrial
action which resulted in a retrospective increase in the NHS Tariff (the payment
mechanism used for outsourced NHS activity) back to April 2024. The 2025 full year
revenue and margin benefit is expected to be c£750k and c£275k respectively. Since
the period end, good progress has been made in all areas including onboarding additional
consultants and commencing initial commercial discussions with four new independent
hospitals with a view to placing work in Q4 and FY 26. We also anticipate submitting
full planning for the first surgical hub early in Q4. Taking these factors into 
account we approach FY 25 with good confidence that we will be in line with current
market expectations on a revenue and underlying EBITDA basis.

Share on:
